Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20066540 | 1.00 | S1PR4 (0.32) | S1PR4S1PR1S1PR3S1PR5CNR2 | |
| SCHEMBL23692666 | 1.00 | S1PR4 (0.32) | S1PR4S1PR1S1PR3S1PR5CNR2 | |
| SCHEMBL25979519 | 0.86 | CNR2 (0.36) | S1PR4S1PR1S1PR3S1PR5CNR2 | |
| SCHEMBL21719757 | 0.73 | CNR2 (0.32) | CNR2 | |
| SCHEMBL19261280 | 0.72 | CNR2 (0.33) | S1PR4S1PR1S1PR3S1PR5CNR2 | |
| SCHEMBL22058479 | 0.72 | CNR2 (0.33) | S1PR4S1PR1S1PR3S1PR5CNR2 | |
| SCHEMBL22023930 | 0.72 | KDR (0.32) | CNR2 | |
| SCHEMBL19788362 | 0.72 | KDR (0.32) | CNR2 | |
| SCHEMBL20307212 | 0.72 | CNR2 (0.33) | S1PR4S1PR1S1PR3S1PR5CNR2 | |
| SCHEMBL21719823 | 0.72 | KDR (0.32) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230069174-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-03-02 | — | — | US | disclosed |
| US-9908877-B2 | Imidazo[1,5-a]pyridinium ion fluorophores, and methods of making and using the same | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230069174-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | ENPP2, NMT2, NMT1 | S1PR4 4338/4885S1PR1 3656/4885S1PR3 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.